Amgen — Apr 30, 2026 release

$Billions, except shares Q1 ’26 Q1 ’25 YOY Δ Operating Cash Flow $ 2.2  $ 1.4  $ 0.8  Capital Expenditures $ 0.7  $ 0.4  $ 0.3  Free Cash Flow $ 1.5  $ 1.0  $ 0.5  Dividends Paid $ 1.4  $ 1.3  $ 0.1  Share Repurchases $ 0.0  $ 0.0  $ 0.0  Average Diluted Shares (millions) 544  541  3  Note: Numbers may not add due to rounding $Billions 3/31/26 12/31/25 YTD Δ Cash and Cash Equivalents $ 12.0  $ 9.1  $ 2.9  Debt Outstanding $ 57.3  $ 54.6  $ 2.7  Note: Numbers may not add due to rounding AMGEN REPORTS FIRST QUARTER 2026 FINANCIAL RESULTS Page 7 2026 Guidance For the full year 2026, the Company expects: • Total revenues in the range of $37.1 billion to $38.5 billion. • On a GAAP basis, EPS in the range of $15.62 to $17.10, and a tax rate in the range of 14.5% to 16.0%. • On a non-GAAP basis, EPS in the range of $21.70 to $23.10, and a tax rate in the range of 15.0% to 16.5%. • Capital expenditures to be approximately $2.6 billion. • Share repurchases not to exceed $3.0 billion. First Quarter Product and Pipeline Update The Company provided the following updates on selected product and pipeline programs: General Medicine MariTide (maridebart cafraglutide, AMG 133) • MariTide is a differentiated antibody-peptide conjugate that activates the glucagon like peptide 1 (GLP-1) receptor and antagonizes the glucose-dependent insulinotropic polypeptide receptor (GIPR) featuring monthly or less frequent dosing. • MARITIME-1, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, without Type 2 diabetes (T2D). • MARITIME-2, a Phase 3 study of MariTide for chronic weight management, is ongoing in adults living with obesity or overweight, with T2D. • MARITIME-CV, a Phase 3 study of MariTide on cardiovascular (CV) outcomes, is enrolling adults living with established atherosclerotic cardiovascular